96 Tests PN: B212278

Components:

45x Ab-conjugated beads (S5P5 - Mouse BLC Ab-bead). PN: B212278A. One vial containing 100 µL of anti-mouse BLC conjugated to AimPlex Bead S5P5.

25x Biotin-detection Ab (Mouse BLC Biotin-dAb). PN: B212278B. One vial containing 100 µL of biotinylated anti-mouse BLC.

Lyophilized Standard Mix - Mouse Group 4 Panel B, 11-Plex. PN: MG4011B. One vial containing lyophilized recombinant 6CKine, Activin A, BDNF, BLC, BRAK, MDC, MIP-1γ, MIP-3β, OPG, TARC, and TIMP-1.  Note: If multiple analyte kits on the above target list are ordered as a panel, only one vial of standard mix is supplied for those analyte kits.

Application: Optimal antibody pair and antigen standard for assaying human Mouse CXCL13/BCA-1/BLC. Can be multiplexed with other analytes in Mouse Group 4. To be used in conjunction with the AimPlex Mouse/Rat Basic Kit (PN: P200201) and a diluent kit. Refer to the AimPlex Multiplex Immunoassay User Manual and kit inserts for the assay procedure.

Storage:  2-8 C in the dark.

Important: Sodium azide forms explosive compounds with heavy metals. These products contain <0.05% (w/w) azide which with repeated contact with lead and copper commonly found in plumbing drains may result in the buildup of shock sensitive compounds. Dispose in accordance with regulations from your institute.

For Research Use Only. Not for use in diagnostic procedures.

Assay Specifications:

  • Sample types: Cell culture supernatant, serum, plasma, bodily fluid and tissue/cell lysate

  • Sensitivity (LOD): < 10 pg/mL

  • Quantitation range:

  • LLOQ: < 20 pg/mL

  • ULOQ: > 5,000 pg/mL

  • Standard dose recovery: 70-130%

  • Intra-assay CV: < 10%

  • Inter-assay CV: < 20%

  • Cross-reactivity of analytes in Mouse Group 4: Negligible

  • Sample volume: 15 µL/test

Description:

CXCL13, also known as B lymphocyte chemoattractant (BLC) or B cell-attracting chemokine 1 (BCA-1), is a protein.  As its name suggests, this chemokine is selectively chemotactic for B cells belonging to both the B-1 and B-2 subsets, and elicits its effects by interacting with chemokine receptor CXCR5.  CXCL13 and its receptor CXCR5 control the organization of B cells within follicles of lymphoid tissues and is expressed highly in the liver, spleen, lymph nodes, and gut of humans.  In T lymphocytes, CXCL13 expression is thought to reflect a germinal center origin of the T cell, particularly a subset of T cells called follicular B helper T cells (or TFH cells). Hence, expression of CXCL13 in T-cell lymphomas, such as Angioimmunoblastic T-cell Lymphoma, is thought to reflect a germinal center origin of the neoplastic T-cells. Diseases associated with CXCL13 include thymic hyperplasia and follicular dendritic cell sarcoma.

References:

  1. Legler DF, Loetscher M, Roos RS, Clark-Lewis I, Baggiolini M, Moser B (February 1998). "B cell-attracting chemokine 1, a human CXC chemokine expressed in lymphoid tissues, selectively attracts B lymphocytes via BLR1/CXCR5". J. Exp. Med. 187 (4): 655–60. doi:10.1084/jem.187.4.655. PMC 2212150. PMID 9463416.

  2. Gunn MD, Ngo VN, Ansel KM, Ekland EH, Cyster JG, Williams LT (February 1998). "A B-cell-homing chemokine made in lymphoid follicles activates Burkitt's lymphoma receptor-1". Nature 391 (6669): 799–803. doi:10.1038/35876. PMID 9486651.

  3. Ansel KM, Harris RB, Cyster JG (January 2002). "CXCL13 is required for B1 cell homing, natural antibody production, and body cavity immunity". Immunity 16 (1): 67–76. doi:10.1016/S1074-7613(01)00257-6. PMID 11825566.

  4. Ansel KM, Ngo VN, Hyman PL, Luther SA, Förster R, Sedgwick JD, Browning JL, Lipp M, Cyster JG (July 2000). "A chemokine-driven positive feedback loop organizes lymphoid follicles". Nature 406 (6793): 309–14. doi:10.1038/35018581. PMID 10917533.